ArticleFrontiers in oncology2025
Maintenance therapy in hormone receptor-positive and human epidermal growth factor receptor 2-positive metastatic breast cancer: a real-world multicenter retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The optimal choice of maintenance therapy after standard first-line treatment for hormone receptor (HR)-and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) remains uncertain. Therefore, we evaluated the clinical value of trastuzumab combined with endocrine therapy (ET group) compared with trastuzumab combined with chemotherapy (CT group) as maintenance therapy in patients with HR+/HER2+ MBC. Methods: The clinical data of 117 patients with HR+/HER2+ MBC who received trastuzumab combined with endocrine therapy or chemotherapy as maintenance therapy at three hospitals in China between January 2012 and October 2022 were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). To construct a nomogram, a Cox regression model was used for both the univariate and multivariate analyses. The predictive ability and accuracy of the nomogram were assessed using the concordance index and calibration curves. Results: Herein, 73 and 44 patients were assigned to the ET and CT groups, respectively. PFS was significantly longer in the ET group than the CT group (median PFS, 10.8 months vs. 7.2 months; adjusted hazard ratio, 0.68; 95% confidence interval, 0.46 to 0.99]; p=0.039). Based on the results of the multivariate analysis, a nomogram was established, which enabled visual risk prediction and demonstrated acceptable predictive ability. Discussion: Maintenance therapy using trastuzumab combined with endocrine therapy following standard first-line treatment may improve the survival and safety of patients with HR+/HER2+ MBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.